Physician profile
Heather Chen
NPI 1164881603
$3,875.97
in general payments reported to CMS, 2019-2025
20 companies · $938 in 2025
The $938 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $11.98 · 2021: $455 · 2022: $686 · 2023: $559 · 2024: $1,082 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $802.18 | 2019-2025 | Clareon, Hydrus Microstent, Tryptyr |
| Glaukos Corporation | $654.87 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $446.53 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $376.13 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Harrow Eye, LLC | $345.54 | 2024-2025 | Vevye, Natacyn |
| Tarsus Pharmaceuticals, INC. | $270.70 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $260.03 | 2021 | |
| Oyster Point Pharma, INC. | $209.09 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sight Sciences, INC. | $120.39 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Mallinckrodt Hospital Products INC. | $104.10 | 2021-2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $46.13 | 2022 | |
| Thea Pharma INC. | $41.52 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $39.01 | 2021 | |
| Amgen INC. | $28.18 | 2025 | Tepezza |
| Dompe US, INC. | $28.17 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $24.69 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.14 | 2021 | |
| Biotissue Holdings INC. | $20.12 | 2022 | |
| Eyevance Pharmaceuticals LLC | $18.37 | 2023 | Flarex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.